Publications

1. GVS advice fostamatinib (Tavlesse®) for the treatment of chronic immune thrombocytopenia

   The National Health Care Institute has completed its assessment whether the medicinal product fostamatinib (Tavlesse®) is ...

   Report | 06-12-2022

2. GVS advice doxylamine succinate/pyridoxine hydrochloride (Xonvea®) for the treatment of nausea and vomiting during pregnancy

   The National Health Care Institute has completed its assessment whether the medicinal product doxylamine succinate/pyridoxine ...

   Report | 29-11-2022

3. GVS advice baloxavir marboxil (Xofluza®)

   The National Health Care Institute has completed its assessment whether the product baloxavir marboxil (Xofluza®) is ...

   Report | 24-11-2022

4. GVS advice on liraglutide (Saxenda®) and naltrexon/ bupropion (Mysimba®) extension of further conditions

   The National Health Care Institute has completed its assessment whether the List 2 conditions for liraglutide (Saxenda®) and ...

   Report | 23-11-2022

5. GVS advice to include house dust mite extract 300 IR HDM (Actair®)

   The National Health Care Institute has completed its assessment whether house dust mite extract 300 IR HDM (Actair®) can be ...

   Report | 10-11-2022

6. Package advice pralsetinib (Gavreto®) for the treatment of non-small cell lung carcinoma (NSCLC)

   The National Health Care Insititue has completed its assessment whether pralsetinib (Gavreto®) can be included in the basic ...

   Report | 10-11-2022

7. Progress of the conditional inclusion process for rhPTH 1-84 (Natpar®)

   The National Health Care Institute advises the Director of Pharmaceuticals and Medical Technology at the Ministry of Health, ...

   Report | 02-11-2022

8. GVS advice nirmatrelvir/ritonavir (Paxlovid®) for the treatment of COVID-19

   The National Health Care Institute has assessed whether nirmatrelvir/ritonavir (Paxlovid®) can be included in the Medicine ...

   Report | 27-10-2022

9. GVS advice on natalizumab SC (Tysabri®) for adult patients with highly active RRMS

   The National Health Care Institute has completed its assessment whether natalizumab SC (Tysabri®) can be included in the Medicine ...

   Report | 25-10-2022

10. Package advice on ciltacabtagene autoleucel (Carvykti®) for the treatment of relapsing and refractory multiple myeloma (RRMM)

    The National Health Care Institute advises the Minister not to include ciltacabtagene autoleucel (Carvykti®) for the treatment of ...

    Report | 20-10-2022